title: Corticosteroid-induced central serous chorioretinopathy.
abstract: Five patients were identified by medical records and fluorescein angiography as having developed central serous chorioretinopathy (CSC) during corticosteroid treatment. These five and 28 previously reported corticosteroid-induced CSC occurrences were studied to clarify the differences between idiopathic CSC and corticosteroid-induced CSC. Nine previously reported occurrences of corticosteroid-induced multiple posterior pigment epitheliopathy (MPPE) were also reviewed. Corticosteroid-induced CSC patients were older and less male-dominant; in MPPE, female patients predominated and most had bilateral involvement. The onset of CSC was within 70 days of corticosteroid administration in the short latency group, and more than 6 months after administration in the prolonged latency group. Daily doses of prednisolone usually exceeded 20 mg in the short latency group and was less than 20 mg in the prolonged latency group. Immunosuppressive agents such as cyclophosphamide were related to a lower daily dose at onset.
authors.affiliation: Department of Ophthalmology, Kitasato University School of Medicine, Kanagawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Wakakura
authors.forename: E
authors.initials: E
authors.lastname: Song
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
mesh_terms: D000328:Adult; D001623:Betamethasone / Q000009:adverse effects / Q000627:therapeutic use; D015862:Choroid Diseases / Q000139:chemically induced* / Q000473:pathology; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010857:Pigment Epithelium of Eye / Q000187:drug effects / Q000473:pathology; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012164:Retinal Diseases / Q000139:chemically induced* / Q000473:pathology
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D001623:Betamethasone; D011239:Prednisolone; D008775:Methylprednisolone